Patents by Inventor Kate Jones

Kate Jones has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of treatment for prevention of glucocorticoid toxicity and/or enhancement of muscle regeneration via neutrophil elastase inhibition
    Patent number: 11918570
    Abstract: The present disclosure is directed to methods of treatment, including treatment of a myopathy by administering to a subject in need thereof an elastase inhibitor in combination with a glucocorticoid. The present disclosure is also directed to pharmaceutical compositions that include an elastase inhibitor that can be used in such treatment.
    Type: Grant
    Filed: April 13, 2021
    Date of Patent: March 5, 2024
    Assignees: The Research Foundation for The State University of New York, The University of Liverpool
    Inventors: Addolorata Pisconti, Fiona Kate Jones, Kirsty Anne Johnson
  • METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITION
    Publication number: 20210315873
    Abstract: The present disclosure is directed to methods of treatment, including treatment of a myopathy by administering to a subject in need thereof an elastase inhibitor in combination with a glucocorticoid. The present disclosure is also directed to pharmaceutical compositions that include an elastase inhibitor that can be used in such treatment.
    Type: Application
    Filed: April 13, 2021
    Publication date: October 14, 2021
    Applicants: The Research Foundation for The State University of New York, The University of Liverpool
    Inventors: Addolorata Pisconti, Fiona Kate Jones, Kirsty Anne Johnson
  • Antagonists against TNFR1 and methods of use therefor
    Patent number: 9028822
    Abstract: The invention provides methods for treating inflammatory diseases (e.g., chronic inflammatory diseases) comprising administering an antagonist of Tumor Necrosis Factor Receptor 1. The invention also provides ligands that contain an immunoglobulin single variable domain (domain antibody, dAb) monomer that binds Tumor Necrosis Factor Receptor 1, and methods of using the ligands. Also provided are nucleic acids encoding the ligands, recombinant host cells and methods for preparing the ligands.
    Type: Grant
    Filed: July 13, 2011
    Date of Patent: May 12, 2015
    Assignee: Domantis Limited
    Inventors: Neil D. Brewis, Benjamin P. Woolven, Steve Holmes, Ian M. Tomlinson, Jennifer Lee, Carolyn Enever, Amrik Basran, Kate Jones, Ruud de Wildt, Stanislas Blein
  • ANTAGONISTS AGAINST TNFR1 AND METHODS OF USE THEREFOR
    Publication number: 20130022605
    Abstract: The invention provides methods for treating inflammatory diseases (e.g., chronic inflammatory diseases) comprising administering an antagonist of Tumor Necrosis Factor Receptor 1. The invention also provides ligands that contain an immunoglobulin single variable domain (domain antibody, dAb) monomer that binds Tumor Necrosis Factor Receptor 1, and methods of using the ligands. Also provided are nucleic acids encoding the ligands, recombinant host cells and methods for preparing the ligands.
    Type: Application
    Filed: July 13, 2011
    Publication date: January 24, 2013
    Inventors: Neil D. Brewis, Benjamin P. Woolven, Steven Holmes, Ian M. Tomlinson, Jennifer Lee, Carolyn Enever, Amrik Basran, Kate Jones, Ruud de Wildt, Stanislas Blein